Close Menu
April 17, 2019
Sponsored by
Isoplexis

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

GenomeWebinar

Associate Professor, Department of Leukemia, MD Anderson Cancer Center

Director, New Collaborations, Isoplexis

This webinar provides an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

Checkpoint immunotherapy has proven to be a powerful therapeutic against a variety of cancers, yet due to response rates that range between 20 percent and 40 percent, researchers and drug developers continue to seek ways to indicate response or non-response as early as possible. A particular area of focus is biomarkers that can assess the status of the pre-therapy tumor microenvironment in order to predict response.

Our speaker, Naval Daver of MD Anderson Cancer Center, discusses advanced immune-based approaches in acute myeloid leukemia that combine chemotherapy with checkpoint therapy, along with the relevant biomarker strategies associated with each.

Dr. Daver also describes a study based on a single-cell cytokine analysis system and Polyfunctional Strength Index (PSI) from Isoplexis that demonstrated that certain cytokine potency contributors, in particular from stimulatory cytokines, correlate with overall survival.

In addition, Jon Chen of Isoplexis shares several case studies using tumor-infiltrating lymphocytes in combination checkpoint immunotherapy that correlate polyfunction to outcome.

*Due to the location of our speakers, this webinar is pre-recorded.

Sponsored by

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.

Jun
04
Sponsored by
NanoCellect

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance. 

Jun
06
Sponsored by
NRGene & Illumina

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.